Cue Biopharma
CUE
74 hedge funds and large institutions have $31M invested in Cue Biopharma in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 10 closing their positions.
232% more call options, than puts
Call options by funds: $292K | Put options by funds: $88K
0.1% more ownership
Funds ownership: 1.11% → 1.21% (+0.1%)
8% less funds holding
Funds holding: 80 → 74 (-6)
22% less capital invested
Capital invested by funds: $39.7M → $31M (-$8.76M)
33% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 27
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
+$2.35M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$459K |
| 3 |
Renaissance Technologies
New York
|
+$439K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$354K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$346K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$422K |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
-$235K |
| 3 |
BlackRock
New York
|
-$223K |
| 4 |
AC
Annandale Capital
Dallas,
Texas
|
-$172K |
| 5 |
Jane Street
New York
|
-$144K |
CUE Hedge Fund Activity: Q1 2024 in Review
74 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2024, worth a combined $31M — down 22% from $39.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CUE and 4 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 18 added.
The largest buyer was Bleichroeder LP, adding an estimated $2.35M. The largest seller was Morgan Stanley, cutting an estimated $422K.
- 74 institutional investors held Cue Biopharma (CUE) as of Q1 2024, down from 80 in Q4 2023.
- Funds reported $31M of Cue Biopharma stock for Q1 2024, down 22% quarter-over-quarter.
- 4 funds opened new Cue Biopharma positions in Q1 2024 and 10 closed out, a net change of -6 holders.
- The largest Cue Biopharma buyer in Q1 2024 was Bleichroeder LP, an estimated $2.35M added.
- The largest Cue Biopharma seller in Q1 2024 was Morgan Stanley, an estimated $422K sold.
Based on aggregated 13F filings for Q1 2024.